Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Rothfels, Karen, 2020-09-28

Class:IdInstanceEdit:9701908
_displayNameRothfels, Karen, 2020-09-28
_timestamp2020-09-28 00:25:52
author[Person:1226097] Rothfels, Karen
dateTime2020-09-28 00:25:46
(modified)[Pathway:201556] Signaling by ALK [Homo sapiens]
[EntityWithAccessionedSequence:9699801] ALK F1174L [plasma membrane] [Homo sapiens]
[EntityWithAccessionedSequence:9699836] ALK G1128A [plasma membrane] [Homo sapiens]
[EntityWithAccessionedSequence:9699837] ALK I1250T [plasma membrane] [Homo sapiens]
[EntityWithAccessionedSequence:9699853] ALK R1275Q [plasma membrane] [Homo sapiens]
[CandidateSet:9700077] p-7Y kinase domain ALK mutant dimers [plasma membrane] [Homo sapiens]
[DefinedSet:9700081] NVP-TAE684-sensitive ALK mutants [cytosol] [Homo sapiens]
[CandidateSet:9700082] kinase domain ALK mutant dimers [plasma membrane] [Homo sapiens]
[CandidateSet:9700083] kinase domain ALK mutants [plasma membrane] [Homo sapiens]
[PathwayDiagram:9700218] Diagram of Signaling by ALK, Signaling by ALK fusions and activated point mutants, ALK mutants bind TKIs, ASP-3026- resistant ALK mutants, NVP-TAE684-resistant ALK mutants, alectinib resistant ALK mutants, brigatinib-resistant ALK mutants, ceritinib-resistant ALK mutants, crizotinib-resistant ALK mutants, and lorlatinib-resistant ALK mutants
List all 18 refering instances
[Change default viewing format]
No pathways have been reviewed or authored by Rothfels, Karen, 2020-09-28 (9701908)
Follow Reactome